Opportunity Information: Apply for RFA CA 11 501
Apply for RFA CA 11 501
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Childhood Cancer Survivor Study (CCSS)(Limited Competition U24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.395 Cancer Treatment Research.
- This funding opportunity was created on Feb 17, 2011 and posted on Feb 17, 2011.
- Applicants must submit their applications by Apr 21, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $4,380,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Childhood Cancer Survivor Study (CCSS) (Limited Competition U24) funding opportunity, issued by the National Institutes of Health (NIH), is designed to continue federal support for the CCSS as a long-standing, multi-institution resource for research on the long-term outcomes of childhood cancer survivors. The core idea behind this announcement is not simply to fund a single, narrow research project, but to maintain and operate a major shared infrastructure that enables many investigators to study how pediatric cancers and their treatments affect survivors later in life. In practice, this means supporting the systems, coordination, and data resources needed to carry out broad, high-quality studies on late effects, including physical health conditions as well as behavioral and sociodemographic outcomes.
CCSS is described as a comprehensive multicenter effort built around managing very large cohorts of individuals who survived childhood cancers, along with comparison participants. The original cohort includes 14,370 survivors who were diagnosed between 1970 and 1986, plus 3,737 siblings who serve as a comparison group for certain analyses. The FOA also highlights expansion through a second cohort expected to be completed by the end of the then-current award period, consisting of a similar number of survivors diagnosed between 1987 and 1999. By spanning these diagnosis eras, the resource is positioned to help researchers examine how evolving treatment approaches over time may translate into different late-effect profiles, risks, and quality-of-life outcomes across decades of survivorship.
Structurally, the CCSS at the time of the announcement involves 27 participating institutions, primarily in the United States with additional participation in Canada. That multi-site footprint matters because it supports large-scale follow-up, improves the diversity and size of the survivor population available for study, and allows for coordinated data collection and long-term tracking across institutions. The FOA frames CCSS as an enabling platform for the broader research community, emphasizing its role in quantifying and improving understanding of the downstream effects of pediatric cancer therapy on later health and life outcomes.
From an administrative standpoint, this opportunity is a discretionary NIH cooperative agreement (funding instrument type: U24). A cooperative agreement typically indicates substantial scientific or programmatic involvement by the funding agency compared with a standard grant, reflecting the expectation of close coordination between NIH and the award recipient to ensure the resource continues to function effectively and remains broadly useful to the field. The activity category is listed under education and health, with the CFDA number 93.395 (Cancer Treatment Research). The FOA anticipated a single award, with an estimated total funding level of $4,380,000, and it did not require cost sharing or matching.
Eligibility, as summarized in the listing, included nonprofit organizations, including both nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status (other than institutions of higher education). The opportunity was posted on February 17, 2011, with an original and current closing date of April 21, 2011, and an archive date of May 22, 2011. The funding opportunity number is RFA-CA-11-501, and the full announcement was hosted through the NIH grants guide. For access or technical issues, the provided contact route was the NIH Office of Extramural Research (OER) webmaster email.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is an NIH funding opportunity to continue federal support for the Childhood Cancer Survivor Study (CCSS) as a long-standing, multi-institution resource that enables research on the long-term outcomes of childhood cancer survivors.
What is the official name of the opportunity?
The opportunity is titled "The Childhood Cancer Survivor Study (CCSS) (Limited Competition U24)."
Which federal agency is offering this opportunity?
The opportunity is issued by the National Institutes of Health (NIH).
What is the purpose of the CCSS award described here?
The purpose is to maintain and operate a major shared research infrastructure, including the systems, coordination, and data resources needed to support broad, high-quality studies on late effects of pediatric cancer and its treatments.
Is this meant to fund a single research project?
No. The announcement emphasizes that the goal is not to fund one narrow research project, but to sustain CCSS as a shared platform and resource that supports many investigators and many studies focused on long-term survivorship outcomes.
What kinds of outcomes does CCSS support research on?
The resource is intended to enable research on late effects, including physical health conditions as well as behavioral and sociodemographic outcomes in survivors of childhood cancer.
What makes CCSS a "resource" rather than a typical study?
CCSS is described as a comprehensive multicenter effort centered on managing very large survivor cohorts (plus comparison participants) and maintaining the infrastructure needed for coordinated, long-term follow-up and data collection across many institutions.
What are the cohorts included in CCSS as described in this announcement?
The original cohort includes 14,370 childhood cancer survivors diagnosed between 1970 and 1986, plus 3,737 siblings who serve as a comparison group for certain analyses. The announcement also highlights expansion through a second cohort expected to be completed by the end of the then-current award period, consisting of a similar number of survivors diagnosed between 1987 and 1999.
Why does the announcement emphasize survivors diagnosed across different treatment eras?
Because including survivors diagnosed in different eras (1970-1986 and 1987-1999) positions the resource to help researchers examine how changing treatment approaches over time may translate into different late-effect profiles, risks, and quality-of-life outcomes across decades of survivorship.
Who is included as a comparison group in CCSS?
As described, 3,737 siblings are included as a comparison group for certain analyses.
How many institutions participate in CCSS?
The CCSS structure described in the announcement includes 27 participating institutions.
Are participating institutions limited to the United States?
No. The participating institutions are primarily in the United States, with additional participation in Canada.
Why does the multicenter structure matter for this resource?
The multi-site footprint supports large-scale follow-up, improves the diversity and size of the survivor population available for study, and enables coordinated data collection and long-term tracking across institutions.
What type of award mechanism is used?
This opportunity uses an NIH cooperative agreement with the funding instrument type U24.
What does it mean that this is a cooperative agreement (U24)?
As described, a cooperative agreement typically indicates substantial scientific or programmatic involvement by the funding agency compared with a standard grant, reflecting close coordination between NIH and the award recipient to ensure the resource continues to function effectively and remains broadly useful to the field.
What is the activity category listed for this opportunity?
The activity category is listed under education and health.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.395 (Cancer Treatment Research).
How many awards did NIH anticipate making?
The announcement anticipated a single award.
What was the estimated total funding level?
The estimated total funding level was $4,380,000.
Was cost sharing or matching required?
No. The listing states that cost sharing or matching was not required.
Who was eligible to apply based on the listing summary?
Eligibility included nonprofit organizations, including nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status (other than institutions of higher education).
What is the funding opportunity number?
The funding opportunity number is RFA-CA-11-501.
When was the opportunity posted?
The opportunity was posted on February 17, 2011.
What were the closing dates for applications?
The original and current closing date listed was April 21, 2011.
When was the opportunity archived?
The archive date was May 22, 2011.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide.
Who should be contacted for access or technical issues?
For access or technical issues, the contact route provided was the NIH Office of Extramural Research (OER) webmaster email.
Browse more opportunities from the same category: Education Health
Next opportunity: NIH HMO Collaboratory Coordinating Center Limited Competition (U54)
Previous opportunity: The Placebo Effect Mechanisms and Methodology (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 11 501
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 11 501) also looked into and applied for these:
| Funding Opportunity |
|---|
| Medication Initiative for Tobacco Dependence (MITD) A New Product Development Partnership (PDP)(UH2/UH3) Apply for RFA DA 11 015 Funding Number: RFA DA 11 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Centers in Minority Institutions Program (G12) Apply for PAR 11 132 Funding Number: PAR 11 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Institutional Training Grants for Research Training in Biomedical Informatics (T 15) Apply for RFA LM 11 001 Funding Number: RFA LM 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition National Primate Research Centers (P51) Apply for PAR 11 136 Funding Number: PAR 11 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development and Translation of Medical Technologies to Reduce Health Disparities (R43/R44) Apply for RFA EB 11 001 Funding Number: RFA EB 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01) Apply for PAR 11 150 Funding Number: PAR 11 150 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) Apply for PAR 11 151 Funding Number: PAR 11 151 Agency: National Institutes of Health Category: Education Health Funding Amount: $680,000 |
| The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01) Apply for PAR 11 152 Funding Number: PAR 11 152 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Basic Cancer Research in Cancer Health Disparities (U01) Apply for PAR 11 156 Funding Number: PAR 11 156 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment (U01) Apply for PAR 11 146 Funding Number: PAR 11 146 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploring Drugs of Abuse and Transgenerational Phenotypes (R01) Apply for RFA DA 12 006 Funding Number: RFA DA 12 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biomarkers of Infection Associated Cancers (R01) Apply for PA 11 158 Funding Number: PA 11 158 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biomarkers of Infection Associated Cancers (R21) Apply for PA 11 159 Funding Number: PA 11 159 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Enhancing Tumoricidal Activity of Natural Killer (NK) Cells by Dietary Components for Cancer Prevention (R01) Apply for PA 11 160 Funding Number: PA 11 160 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Enhancing Tumoricidal Activity of Natural Killer (NK) Cells by Dietary Components for Cancer Prevention (R21) Apply for PA 11 161 Funding Number: PA 11 161 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Effect of Racial and Ethnic Discrimination/Bias on Health Care Delivery (R01) Apply for PA 11 162 Funding Number: PA 11 162 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Effect of Racial and Ethnic Discrimination/Bias on Health Care Delivery (R21) Apply for PA 11 163 Funding Number: PA 11 163 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Effect of Racial and Ethnic Discrimination/Bias on Health Care Delivery (R03) Apply for PA 11 164 Funding Number: PA 11 164 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (UM1) Apply for PAR 11 167 Funding Number: PAR 11 167 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition for Competitive Revision Applications to Accelerate and Enhance Collaborative Translational Science (UL1) Apply for RFA RR 11 004 Funding Number: RFA RR 11 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 11 501", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.